Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes

Abstract Aims/Introduction To evaluate the efficacy and safety of once‐weekly (q.w.) extended‐release exenatide after switching from twice‐daily (b.i.d.) exenatide in patients with type 2 diabetes. Materials and Methods This was an investigator‐initiated, prospective, single‐arm, multicenter study....

Full description

Bibliographic Details
Main Authors: Yuusuke Watanabe, Yoshifumi Saisho, Jun Inaishi, Kinsei Kou, Akira Yamauchi, Yasuhiko Kanazawa, Yoshiaki Okubo, Mikiya Tokui, Takatoshi Imai, Rie Murakami, Tami Tsuchiya, Hironobu Sasaki, Tatsuhiro Masaoka, Junichiro Irie, Shu Meguro, Hiroshi Itoh, for the Twin‐exenatide Study Group
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:Journal of Diabetes Investigation
Subjects:
Glucagon‐like peptide‐1 receptor agonist
Treatment satisfaction
Type 2 diabetes
Online Access:https://doi.org/10.1111/jdi.13146

Internet

https://doi.org/10.1111/jdi.13146

Similar Items